Eli Lilly’s Alzheimer’s drug donanemab rejected for NHS use
The U.K. watchdog declines to endorse Eli Lilly's Alzheimer's drug donanemab, citing lack of value for the NHS and ...
Drug which slows Alzheimer's rejected for NHS use because of 'value'
A new Alzheimer’s drug has been rejected for widespread use in the health service in England after the health spending ...
Jersey Evening Post22m
Donanemab – what we know about the latest Alzheimer’s drug
Donanemab can slow the progression of Alzheimer’s disease.But what is the drug and how does it work? Here your questions on ...
Packet Newspapers22m
Donanemab trial patient: ‘I feel as normal as a 78-year-old can be’
A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal as a 78-year-old can be”. Peter Almond finished a trial for donanemab in ...
Alzheimer’s drug rejected for widespread use by NHS spending watchdog
A new Alzheimer’s drug has been rejected for widespread use in the health service in England after the health spending ...
i24m
Second Alzheimer’s ‘wonder drug’ blocked for use on NHS due to high costs
NHS spending watchdog said donanemab, which would have been available to around 70,000 people in England and Wales, "does not ...
New Alzheimer’s drug rejected for NHS use – because it’s not worth the money
New Alzheimer’s drug rejected for NHS use – because it’s not worth the money - Alzheimer’ patients in UK left behind over ...